Sensus Healthcare announces the launch of its new “Fair Deal Agreement” for the SRT-100 Vision at the AAD 2024 Annual Meeting, held March 8-12 in San Diego. This meeting is the largest gathering of dermatologists in the U.S., hosting more than 10,000 medical personnel at this year’s event. Under the Fair Deal Agreement, dermatology offices gain access to Sensus’ image-guided, award superficial radiotherapy technology to treat non-melanoma skin cancer and keloids under a new service model, with an economic value proposition that’s second to none. Sensus manufactures and sells the only proven, FDA-cleared IG-SRT system and holds a patent for SRT combined with ultrasound, which is deeper and more effective.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRTS:
- Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting
- Sensus Healthcare price target raised to $7.50 from $4 at Alliance Global Partners
- Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
- Sensus Healthcare issued U.S. patent for SRT-100 vision system
- Sensus Healthcare collaborates with CureRays